Thienopyrimidinone derivatives as mGluR1 antagonists
    1.
    发明授权
    Thienopyrimidinone derivatives as mGluR1 antagonists 有权
    噻吩并嘧啶酮衍生物作为mGluR1拮抗剂

    公开(公告)号:US09260448B2

    公开(公告)日:2016-02-16

    申请号:US14038324

    申请日:2013-09-26

    CPC classification number: C07D495/04 A61K31/519

    Abstract: Disclosed are thienopyrimidinone derivatives as antagonists that act on metabotropic glutamate receptor subtype 1. The thienopyrimidinone derivatives show pharmacological activity against metabotropic glutamate receptor-related diseases, including pain, such as neuropathic pain and migraine, psychiatric diseases, such as anxiety disorder and schizophrenia, urinary incontinence, and neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. Also disclosed are methods for preparing the thienopyrimidinone derivatives, and pharmaceutical compositions containing the thienopyrimidinone derivatives as active ingredients.

    Abstract translation: 公开了作为代谢型谷氨酸受体亚型1的拮抗剂的噻吩并嘧啶酮衍生物。噻吩并嘧啶酮衍生物显示针对代谢型谷氨酸受体相关疾病的药理学活性,包括疼痛,如神经性疼痛和偏头痛,精神疾病如焦虑障碍和精神分裂症,尿 失禁和神经变性疾病,如帕金森病和阿尔茨海默病。 还公开了制备噻吩并嘧啶酮衍生物的方法和含有噻吩并嘧啶酮衍生物作为活性成分的药物组合物。

    THIENOPYRIMIDINONE DERIVATIVES AS mGluR1 ANTAGONISTS
    2.
    发明申请
    THIENOPYRIMIDINONE DERIVATIVES AS mGluR1 ANTAGONISTS 有权
    三硝基嘧啶衍生物作为mGluR1拮抗剂

    公开(公告)号:US20140228565A1

    公开(公告)日:2014-08-14

    申请号:US14038324

    申请日:2013-09-26

    CPC classification number: C07D495/04 A61K31/519

    Abstract: Disclosed are thienopyrimidinone derivatives as antagonists that act on metabotropic glutamate receptor subtype 1. The thienopyrimidinone derivatives show pharmacological activity against metabotropic glutamate receptor-related diseases, including pain, such as neuropathic pain and migraine, psychiatric diseases, such as anxiety disorder and schizophrenia, urinary incontinence, and neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. Also disclosed are methods for preparing the thienopyrimidinone derivatives, and pharmaceutical compositions containing the thienopyrimidinone derivatives as active ingredients.

    Abstract translation: 公开了作为代谢型谷氨酸受体亚型1的拮抗剂的噻吩并嘧啶酮衍生物。噻吩并嘧啶酮衍生物显示针对代谢型谷氨酸受体相关疾病的药理学活性,包括疼痛,如神经性疼痛和偏头痛,精神疾病如焦虑障碍和精神分裂症,尿 失禁和神经变性疾病,如帕金森病和阿尔茨海默病。 还公开了制备噻吩并嘧啶酮衍生物的方法和含有噻吩并嘧啶酮衍生物作为活性成分的药物组合物。

Patent Agency Ranking